AmeriHealth Caritas has worked to facilitate vaccine accessibility from adults to the Medicaid managed care organization's youngest members.
The organization and its respective plans have orchestrated efforts across plans to create better vaccine access for all individuals, including partnering with local governments to use AmeriHealth Caritas locations as vaccination sites and hosting COVID-19 vaccination events within local communities.
The FDA-authorized bivalent boosters include protection from Omicron subvariants, BA.4 and BA.5, and are available for children as young as six months old.
Bivalent boosters are approved for all children ages six months and up, regardless of which company manufactured their primary vaccine series.
AmeriHealth Caritas encourages everyone to ask their COVID-19 vaccine provider or pharmacist which kind of vaccine and how many doses they and their family members will need especially as recommendations continue to adjust.
For infants and children who are moderately or severely immunocompromised or have unique conditions, it is best to speak with their provider for specific vaccination guidance.
The CDC website states that COVID-19 vaccines and boosters are safe to administer at the same time as flu or other vaccines, reducing the travel and appointment burden for families.
Annual flu shots are available for children as young as six months and can be received anytime through the winter during the flu season.
AmeriHealth Caritas operates in 12 states and the District of Columbia.
AmeriHealth Caritas serves approximately 5m Medicaid, Medicare, Children's Health Insurance Program, and Health Insurance Marketplace members through its integrated managed care products, pharmaceutical benefit management and specialty pharmacy services, and behavioral health services.
Headquartered in Pennsylvania, AmeriHealth Caritas is a mission-driven organization with nearly 40 years of experience serving low-income and chronically ill populations.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
AstraZeneca increases dividend by 7%
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
Wolters Kluwer enhances Clinical GenAI leadership with AI Labs powered by UpToDate
Amgen announces share dividend for Q2 2024
Virbac expands presence in Japan with Sasaeah acquisition
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva